Endocrinology

This episode covers the upcoming glucose monitor Biolinq Shine, the Insulin Icodec FDA resubmission, and the end of Eli Lilly's work in T2D.

Celebrate 150 episodes of Diabetes Dialogue as hosts reflect on advancements in diabetes technology and impactful discussions in patient care.

The sBLA for insulin human Inhalation Powder in children and adolescents with type 1 or type 2 diabetes was assigned a PDUFA target action date of May 29, 2026.

A recent study indicates the potential benefits of consistent follow-up in diabetes through tele-education, teleconsultation, and digital data support.

Investigators urge clinicians to support teenage patients with type 1 diabetes in managing their blood sugar and transitioning to adult care.

The Q3 recap for endocrinology spotlights major FDA decisions, new guidelines for managing diabetes during pregnancy, and major clinical trial updates.

Catch up on FDA decisions, critical trial results, and expert perspectives on endocrinology.

Lifelong reliance on insulin, constant glucose monitoring, and management of hypo- and hyperglycemia require substantial lifestyle changes.

Yale researchers reveal that 17 million U.S. adolescents and young adults qualify for GLP-1RA therapy, highlighting barriers to access and insurance coverage.

This episode highlights the recent technological advancements made by Medtronic Diabetes in treating type 1 and 2 diabetes.

Explore key FDA decisions in Q4 2025, impacting treatments for atopic dermatitis, chronic rhinosinusitis, and rare diseases.

The resubmission is based on results from 5 randomized clinical trials in the ONWARDS type 2 diabetes phase 3a program.

The approval of the selectively targeted somatostatin receptor type 2 agonist is supported by data from the phase 3 PATHFNDR-1 and PATHFNDR-2 trials.

Biolinq Shine aims to provide continuous glucose monitoring, as well as sleep and activity data, without requiring injections.

This episode highlights the results of the ATTAIN-1 and STEP UP clinical trials, examining the potential of their respective GLP-1 RA subjects.

A significant amount of TED cases go undiagnosed due to a lack of routine screening – Khachikian discusses what is needed to address this problem.

Investigators formulated a series of hypothetical situations to test the overall economic impact of introducing lonapegsomatropin into the growth hormone market.

The investigational oral GLP-1 RA showed superiority in glycemic control and weight loss among patients with uncontrolled T2D.

Tirzepatide saw improvements in A1C and body mass index, which were maintained over the 30-week trial and into the 52-week extension study.

New research from Stockholm, Sweden, has shown the correlation between smoking and insulin sensitivity, with genetic susceptibility increasing the risk further.

Pediatric patients with type 1 diabetes often have severely limited access to care, allowing very few to achieve HbA1c goals.

In addition to type 1 and 2 diabetes, diabetic retinopathy substantially increases the risk of developing and worsening uveitis.

A technology review from the University of Virginia analyzes the successes of AID devices, as well as indicating where the technology still has to go.

Lexicon aims to address concerns from a 2024 complete response letter, which cited an increased risk of diabetic ketoacidosis.

Cadisegliatin, a potential first-in-class oral treatment for type 1 diabetes, has been granted Breakthrough Designation by the FDA.